Summary & Overview
HCPCS J7515: Cyclosporine, Oral, 25 mg
HCPCS Level II code J7515 denotes cyclosporine, oral, 25 mg, an immunosuppressive oral medication used in a range of clinical conditions that require systemic suppression of the immune response. Nationally, accurate coding of oral pharmaceuticals like J7515 matters for pharmacy claims processing, utilization monitoring, and payer coverage determinations. This code is relevant across major national payers, including Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will find a concise overview of what the code represents, payer coverage patterns and benchmarks, common billing considerations, and the clinical context in which oral cyclosporine is typically prescribed. The publication summarizes reimbursement benchmarks, common modifiers used on service lines, and coding relationships where available. It also outlines typical sites of service and service line implications for outpatient pharmacy and clinic dispensing.
Data not available in the input is clearly noted where applicable. This national-level summary is intended to support billing, revenue cycle, and clinical teams in understanding HCPCS Level II code J7515 and its role in outpatient medication billing and reporting.
Billing Code Overview
HCPCS Level II code J7515 represents cyclosporine, oral, 25 mg, a systemic immunosuppressive medication supplied in oral formulation. The service type is medication administration/supply for oral systemic therapy. The typical site of service is outpatient settings including pharmacies, outpatient clinics, and physician office dispensing where oral medications are prescribed and dispensed.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient receiving J7515 (cyclosporine, oral, 25 mg) is an adult or pediatric patient diagnosed with an immune-mediated condition requiring systemic immunosuppression or an ophthalmic disorder for which oral cyclosporine is indicated. Common clinical scenarios include prevention of organ transplant rejection (adjunct immunosuppression), management of severe atopic dermatitis, severe rheumatoid arthritis refractory to first-line therapies, or chronic uveitis when topical therapy alone is insufficient.
The clinical workflow begins with a specialist evaluation (e.g., transplant hepatology/nephrology, dermatology, rheumatology, or ophthalmology). Baseline assessment includes documentation of diagnosis, medication history, baseline labs (complete blood count, renal and hepatic panels, lipid panel), and measurement of blood pressure. Therapeutic drug monitoring of cyclosporine trough levels is typically ordered after initiation and periodically thereafter. The medication is dispensed by a pharmacy and billed using the HCPCS Level II code J7515 for the 25 mg oral unit. Follow-up visits document response, adverse effects (nephrotoxicity, hypertension, neurotoxicity, gingival hyperplasia, hypertrichosis), and any dose adjustments; corresponding lab monitoring is repeated as clinically indicated. Coordination between prescribing provider, specialty pharmacy, and payer prior authorization teams is common prior to dispensing.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|